Amgen Inc. (AMGN) Announces Quarterly Dividend of $1.00
Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Friday, October 14th. Shareholders of record on Wednesday, November 16th will be paid a dividend of 1.00 per share by the medical research company on Thursday, December 8th. This represents a $4.00 annualized dividend and a dividend yield of 2.47%.
Shares of Amgen (NASDAQ:AMGN) opened at 161.90 on Monday. The firm’s 50 day moving average is $169.59 and its 200 day moving average is $162.28. The company has a market cap of $121.16 billion, a PE ratio of 16.57 and a beta of 0.94. Amgen has a 12 month low of $139.02 and a 12 month high of $176.85.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.10. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. Amgen’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.57 EPS. On average, equities analysts predict that Amgen will post $11.35 earnings per share for the current year.
A number of analysts recently weighed in on the stock. Vetr lowered shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $185.76 target price on the stock. in a report on Tuesday, October 4th. Jefferies Group reaffirmed a “buy” rating on shares of Amgen in a report on Wednesday, September 28th. Citigroup Inc. decreased their target price on shares of Amgen from $175.00 to $172.00 and set a “neutral” rating on the stock in a report on Wednesday, September 28th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a report on Wednesday, September 28th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $206.00 target price (up previously from $204.00) on shares of Amgen in a report on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. Amgen currently has an average rating of “Buy” and an average target price of $184.94.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. GAM Holding AG raised its position in shares of Amgen by 32.8% in the second quarter. GAM Holding AG now owns 182,487 shares of the medical research company’s stock valued at $27,765,000 after buying an additional 45,035 shares during the last quarter. Crawford Investment Counsel Inc. raised its position in shares of Amgen by 0.8% in the second quarter. Crawford Investment Counsel Inc. now owns 7,158 shares of the medical research company’s stock valued at $1,089,000 after buying an additional 57 shares during the last quarter. Commonwealth Bank of Australia raised its position in shares of Amgen by 3.8% in the second quarter. Commonwealth Bank of Australia now owns 53,974 shares of the medical research company’s stock valued at $8,214,000 after buying an additional 1,963 shares during the last quarter. Mycio Wealth Partners LLC raised its position in shares of Amgen by 19.3% in the second quarter. Mycio Wealth Partners LLC now owns 3,759 shares of the medical research company’s stock valued at $572,000 after buying an additional 609 shares during the last quarter. Finally, Trexquant Investment LP raised its position in shares of Amgen by 80.7% in the second quarter. Trexquant Investment LP now owns 10,300 shares of the medical research company’s stock valued at $1,567,000 after buying an additional 4,600 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.